Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma

BACKGROUND: Lenvatinib is a first-line agent for advanced hepatocellular carcinoma (HCC), but individual responses to treatment are highly heterogeneous. The aim of this study was to investigate the clinical parameters that influence the efficacy of Lenvatinib and to develop a prognostic model. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaomi, Ding, Xiaoyan, Liu, Mei, Wang, Jingyan, Li, Wei, Chen, Jinglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546830/
https://www.ncbi.nlm.nih.gov/pubmed/37105140
http://dx.doi.org/10.1093/oncolo/oyad107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546830/
https://www.ncbi.nlm.nih.gov/pubmed/37105140
http://dx.doi.org/10.1093/oncolo/oyad107

Ejemplares similares